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Abstract
Background Cellular changes associated with dia-
betic (DG) and idiopathic gastroparesis (IG) have
recently been described from patients enrolled in the
Gastroparesis Clinical Research Consortium. The
association of these cellular changes with gastropare-
sis symptoms and gastric emptying is unknown. The
aim of this study was to relate cellular changes to
symptoms and gastric emptying in patients with
gastroparesis. Methods Earlier, using full thickness
gastric body biopsies from 20 DG, 20 IG, and 20
matched controls, we found decreased interstitial
cells of Cajal (ICC) and enteric nerves and an increase
in immune cells in both DG and IG. Here, demo-
graphic, symptoms [gastroparesis cardinal symptom
index score (GCSI)], and gastric emptying were related
to cellular alterations using Pearson’s correlation
coefficients. Key Results Interstitial cells of Cajal
counts inversely correlated with 4 h gastric retention
in DG but not in IG (r = )0.6, P = 0.008, DG, r = 0.2,
P = 0.4, IG). There was also a significant correlation
between loss of ICC and enteric nerves in DG but not
in IG (r = 0.5, P = 0.03 for DG, r = 0.3, P = 0.16, IG).
Idiopathic gastroparesis with a myenteric immune
infiltrate scored higher on the average GCSI (3.6 ± 0.7
vs 2.7 ± 0.9, P = 0.05) and nausea score (3.8 ± 0.9 vs
2.6 ± 1.0, P = 0.02) as compared to those without an
infiltrate. Conclusions & Inferences In DG, loss of
ICC is associated with delayed gastric emptying.
Interstitial cells of Cajal or enteric nerve loss did not
correlate with symptom severity. Overall clinical
severity and nausea in IG is associated with a myen-
teric immune infiltrate. Thus, full thickness gastric
biopsies can help define specific cellular abnormalities
in gastroparesis, some of which are associated
with physiological and clinical characteristics of
gastroparesis.
Keywords clinical symptoms, enteric nervous system,
gastric emptying, gastroparesis, interstitial cells of
Cajal, macrophages.
INTRODUCTION
Gastroparesis is a gastric motility disorder character-
ized by delayed gastric emptying (GE) in the absence of
mechanical obstruction.1 The clinical syndrome com-
prises of nausea, vomiting, bloating, early satiety, and
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abdominal pain.2 It is an increasingly recognized
complication of both Type 1 and Type 2 diabetes.3
Other less common causes are post-surgical and med-
ication related, however, a cause remains unknown in
a significant proportion of patients characterized as
idiopathic.4
Gastroparesis-related morbidity seems to be on the
rise. From 1995 to 2004, there has been a 158%
increase in hospitalizations with gastroparesis with
gastroparetics incurring higher hospitalization costs
compared to other upper gastrointestinal (GI) disor-
ders.5 The age-adjusted incidence of gastroparesis per
100 000 person-years was 2.4 for men and 9.8 for
women for years 1996–2006 from Olmsted County,
Minnesota and corresponding prevalence figures were
9.6 for men and 37.8 for women per 100 000 persons.
In this study, overall survival was found to be
significantly lower than the age- and sex-specific
survival of general population.6 In spite of increasing
recognition and morbidity associated with the condi-
tion in last two decades, therapeutic options continue
to remain limited at best. A major limiting factor in
the development of targeted therapy is the lack of
understanding of cellular etiopathogenesis in human
gastroparesis.7
A few retrospective studies have defined abnormal-
ities in cell types required for a normal gastric function
such as loss of interstitial cells of Cajal (ICC) and
neuronal nitric oxide synthase (nNOS).8–11 Loss of ICC
has been associated with gastric dysrhythmias and
worse clinical symptoms.12,13 Until recently, detailed
analysis of various cell types, including the extrinsic
innervation to the stomach, enteric nerves, glia,
smooth muscle cells, ICC, and immune cells was not
available. To meet this need, the National Institutes of
Diabetes and Digestive and Kidney Diseases (NIDDK)
Gastroparesis Clinical Research Consortium(GpCRC)
was established in 2006 to prospectively enroll
patients, obtain detailed clinical data and collect full
thickness gastric tissue in a standardized approach. We
recently described the cellular changes associated with
diabetic (DG) and idiopathic (IG) gastroparesis from
GpCRC patients.14 On quantitative comparisons, the
most commonly observed findings were loss of ICC
and an immune infiltrate characterized by an increase
in CD45 and CD68 immunoreactivity in both DG and
IG. A 14–17% decrease in the number of enteric nerve
fibers as defined by Protein Gene Product 9.5 (PGP9.5)
immunoreactivity was also seen. Less common were
changes in nNOS, vasoactive intestinal peptide (VIP),
substance P (SP), and tyrosine hydroxylase (TH).
The primary aim of this study was to determine
associations, in both DG and IG, between specific
histological markers of gastroparesis (ICC loss, nerve
fiber loss and immune infiltrate) and specific clinical
features (scintigraphically determined impairment in
GE and worsening in standardized symptom scores).
A secondary aim was to explore associations of less
commonly histological features such as nNOS, SP,
VIP, and TH expression with GE and clinical
symptoms.
METHODS
Subject enrollment
The NIDDK GpCRC consists of a network of seven centers and
one data coordinating center collaborating for research on gastro-
paresis. The Gastroparesis Registry is an observational study to
clarify the epidemiology, natural history, clinical course, and
other outcomes of gastroparesis (ClinicalTrials.gov identifier:
NCT00398801). The Gastroparesis Registry consists of patients
>18 years of age with symptoms of at least 12 week duration,
delayed GE on scintigraphy (>60% retention at 2 h or >10%
retention at 4 h), and no evidence of obstruction. Exclusion
criteria included presence of active inflammatory bowel disease,
eosinophilic gastroenteritis, neurological conditions, acute liver
or renal failure, and history of total or subtotal gastric resection.
Registry data at enrollment include detailed history and physical
examinations, validated symptom questionnaires, upper endo-
scopy, 4 h GE, and laboratory tests.
Clinical questionnaires
Patients were questioned about the onset of their symptoms and
if they had an initial infectious prodrome. Each patient filled out
the 20-item Patient Assessment of Upper Gastrointestinal
Disorders Symptoms Severity Index (PAGI-SYM) questionnaire,
which assesses symptoms of gastroparesis, dyspepsia, and gas-
troesophageal reflux disease. It includes the nine symptoms
consisting the gastroparesis cardinal symptom index (GCSI),
which asks about nausea, retching, vomiting, stomach fullness,
inability to finish a meal, excessive fullness, loss of appetite,
bloating, and abdominal distention.15 The GCSI equals the
summation of the nausea/vomiting subscore (nausea, retching,
and vomiting), postprandial fullness/early satiety subscore (stom-
ach fullness, inability to finish a meal, excessive fullness, and
loss of appetite), and bloating subscore (bloating and large
stomach). Patients were asked to assess the severity of their
symptoms in previous 2 weeks on a 0–5 Likert scale (no
symptoms = 0, very mild = 1, mild = 2, moderate = 3, severe = 4,
very severe = 5).
Gastric emptying
Gastric emptying scintigraphy was performed using a low-fat egg
white meal with imaging at 0, 1, 2, and 4 h after meal ingestion
using the standardized protocol to estimate percent gastric
retention.16 This protocol ensures standardized information about
delayed GE across all participating sites. With this protocol,
delayed GE is characterized by percent gastric retention at any of
the time points and can also be classified according to the gastric
retention at 4 h as mild (£20% gastric retention at 4 h), moderate
(>20–35%), and severe (>35%).2
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Laboratory studies
Laboratory tests obtained on each patient included complete blood
cell count with erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), and glycosylated hemoglobin (HbA1c).
Histology studies
Tissue was obtained from 20 DG and 20 IG patients undergoing
surgery for placement of a gastric stimulator and from 20 years of
age and sex matched patients undergoing duodenal switch gastric
bypass surgery following Institutional Review Board approved
protocols. The full-thickness gastric biopsies were collected in all
subjects from the anterior aspect of the stomach, midway between
the greater and lesser curvatures where the gastroepiploic vessels
meet. Details on tissue acquisition and processing are provided
elsewhere.14 Various components of the enteric nervous system
(ENS) were studied using antibodies to PGP9.5, nNOS, VIP
(inhibitory innervation), SP (excitatory inhibition), and TH
(extrinsic motor innervation). For examining ICC, c-Kit antibody
was used and CD45 was used as a general cell marker for immune
infiltrate.14
Statistical analysis
The histological markers for ICC (c-Kit), enteric nerves (PGP9.5),
and immune infiltrate (CD45) were used for clinical correlations
as outlined in specific aim 1. Patients with marker values ‡25%
compared to normal were categorized as increased on that marker
and those with values £25% compared to normal were categorized
as decreased on that marker. Demographic and other character-
istics were compared between those with and without changes in
these histological markers in both DG and IG using t-test
(continuous characteristics) and chi-squared or Fisher’s exact test
(categorical characteristics). For continuous characteristics,
groups with increased and decreased markers were expressed as
means ± standard deviations. Simple Pearson’s correlation anal-
ysis was done to relate the histological markers (as measured) to
the two key clinical variables indicative of symptoms (average
GCSI score) and delay in gastric emptying (% gastric retention at
4 h). All statistical analyses were carried out using GraphPad 4
software (GraphPad software Inc., La Jolla, CA, USA). A P-value of
<0.05 was considered statistically significant. Exact P-values were
used and these were not corrected for multiple comparisons.
RESULTS
Diabetic gastroparetics
Circular muscle ICC loss There was a 48% decrease in
overall quantification of ICC in DG compared to con-
trols (2.8 ± 0.4 vs 5.3 ± 0.2 cells/high power field,
P < 0.0001). Ten of the 20 patients (50%) with DG were
identified as having depleted number of ICC based on
a ‡ 25% drop. The group with depleted ICC was older
than the group with normal ICC (52.2 ± 13.1 years vs
39.2 ± 11.6 years, P = 0.03) but both groups were sim-
ilar in terms of gender distribution. There were no
differences in terms of diabetes type (Type I or II),
duration or control (determined by HbA1c). The group
with depleted ICC had significantly higher 4 h gastric
retention as compared those with normal ICC
(47.6 ± 25.6% vs 22 ± 9.4%, P = 0.01) as shown in
Table 1. Interstitial cells of Cajal counts and gastric
retention at 4 h were inversely correlated (r = )0.59,
P = 0.008, Fig. 1A). Within the group with depleted
ICC, six patients (60%) had severe gastric retention
(>35% at 4 h) whereas four (40%) had mild to moderate
gastric retention. Of the 10 patients with normal ICC
bodies, only one (10%) had severe gastric retention.
There were no significant correlations between the
average GCSI score and ICC numbers (Fig. 1D)
Myenteric plexus immune cell infiltrate There was an
overall 25% increase in the CD45 expression in DG
when compared to controls (25.5 ± 1.5 vs 20.3 ± 1.1
cells/high power field, P = 0.002). Nine of the 20
patients (45%) with DG were found to have ‡ 25%
increase in CD45 staining cells in the myenteric
plexus. The groups with or without immune infiltrate
were similar in age, sex, or history of infectious pro-
Table 1 Comparisons of gastric retention and gastric symptoms (GCSI) in diabetic or idiopathic gastroparesis patients with and without cellular
alterations: ICC (Kit) loss, enteric nerves (PGP9.5) loss and increased immune infiltrate (CD45)
ICC low
(n = 10)
ICC normal
(n = 10) P
CD45
increased (n = 9)
CD45
normal (n = 11) P
PGP9.5
low (n = 4)
PGP9.5
normal (n = 16) P
Diabetic gastroparesis
% Gastric retention at
4 h (mean ± SD)
47.6 ± 25.6 22 ± 9.4 0.01 39.8 ± 26.5 31.6 ± 20.5 0.46 40.2 ± 20.5 34.2 ± 24.4 0.66
GCSI average score
(mean ± SD)
2.9 ± 1.4 2.8 ± 1.5 0.83 2.8 ± 1.5 2.9 ± 1.4 0.83 2.7 ± 1.6 2.9 ± 1.4 0.79
Idiopathic gastroparesis
% Gastric retention at
4 h (mean ± SD)
17.5 ± 16.8 28.8 ± 16.6 0.17 19.8 ± 15.0 29.6 ± 22.2 0.29 11.2 ± 9.1 26.8 ± 17.8 0.08
GCSI average score
(mean ± SD)
3.7 ± 1.2 3.2 ± 1.0 0.39 3.6 ± 0.7 2.7 ± 0.9 0.05 3.2 ± 0.6 3.3 ± 0.9 0.88
-Nausea 3.6 ± 1.2 3.2 ± 1.0 0.38 3.8 ± 0.9 2.6 ± 1.0 0.02 3.3 ± 1.2 3.5 ± 1.1 0.80
-Fullness 3.6 ± 1.0 3.6 ± 1.2 0.93 3.8 ± 0.9 3.2 ± 1.4 0.31 3.4 ± 1.0 3.7 ± 1.2 0.58
-Bloating 3.3 ± 1.6 2.2 ± 1.8 0.18 2.9 ± 1.6 2.4 ± 1.9 0.54 3.0 ± 1.6 2.7 ± 1.8 0.76
GCSI, gastroparesis cardinal symptom index score; ICC, interstitial cells of Cajal; SD, standard deviation.
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drome. There were no differences in terms of diabetes
type, duration or control. Laboratory parameters such
as leukocyte count, CRP, and ESR were similar in
both the groups. No significant correlations were
found between CD45 infiltrate and GE (Fig. 1B) or
average GCSI (Fig. 1E). The circular muscle CD45
expression was not different in DG when compared to
controls (16.9 ± 0.8 vs 14.3 ± 0.7 cells/high power
field, P = 0.06).
Circular muscle enteric nerve fiber loss There was a
17% overall decrease in the expression of nerve fiber
marker PGP9.5 (36.5 ± 1.8 vs 44.3 ± 2.3 fibers/high
power field, P = 0.01). Only 4 of the 20 patients (20%)
with DG were found to have a PGP9.5 decrease
of ‡ 25%. There were no differences in age, gender,
diabetes type or duration amongst the two groups.
Furthermore, no correlations were found between
PGP9.5 and GE (Fig. 1C) or between PGP9.5 and
average GCSI (Fig. 1F).
Correlation between ICC loss, nerve fiber, and
immune infiltrate There was a significant correlation
between loss of ICC bodies and PGP9.5 fibers in DG
(r = 0.47, P = 0.03) (Fig. 2A). However, immune infil-
trate was not correlated with ICC or nerve fiber loss.
Inhibitory (nNOS, VIP) and excitatory (SP) enteric
nervous system and extrinsic innervation (TH)
(Table 2) shows correlation coefficients between nNOS
positive myenteric neurons, nNOS positive nerve
fibers, VIP, SP, TH with GE, and average GCSI. There
were no significant correlations between these markers
and GE or average GCSI.
Idiopathic gastroparetics
Circular muscle ICC loss There was a 39% decrease in
overall quantification of ICC in IG when compared to
controls (3.2 ± 0.4 vs 5.3 ± 0.2 cells/high power field,
P < 0.0001). Ten of the 20 patients with IG were
characterized as having ICC loss (50%). There was a
similar age and sex distribution amongst those with or
without ICC loss. The ICC loss did not correlate with
gastric emptying as shown in Fig. 3A or average GCSI
(Fig. 3D).
Myenteric plexus immune infiltrate There was an
overall 30% increase in the CD45 expression in IG
when compared to controls (26.5 ± 1.2 vs 20.3 ± 1.1
cells/high power field, P = 0.002). Fourteen of the 20 IG
patients (70%) had ‡ 25% increase. The groups with
and without immune infiltrate did not differ in terms
of age, sex, or history of infection. Leukocyte count,
A B C
D E F
Figure 1 Correlations between % gastric retention at 4 h and average GCSI with ICC, CD45 positive myenteric plexus cells and PGP9.5 positive
nerve fibers in diabetic gastroparesis (A) ICC and % gastric retention at 4 h (r = )0.59, P = 0.008*, slope=)7.3, 95% CI = )12.4 to )2.2), (B) CD45
positive cells and % gastric retention at 4 h (r = 0.05, P = 0.83), (C) PGP9.5 nerve fibers and % gastric retention at 4 h (r = )0.19, P = 0.43), (D) ICC and
GCSI-average (r = 0.10, P = 0.69), (E) CD45 positive cells and GCSI-average (r = 0.13, P = 0.63), (F) PGP9.5 nerve fibers and GCSI-average (r = 0.19,
P = 0.46). *Some graphs have less than 20 data points because of missing data on either the counts, GE or GCSI on these patients.
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CRP, and ESR were similar in both the groups. Overall
GCSI was higher in individuals with myenteric plexus
CD45 infiltrate (3.6 ± 0.7 vs 2.7 ± 0.9, P = 0.05). On
comparing the sub-scores, this was found to be pre-
dominantly secondary to higher nausea score amongst
those with CD45 infiltrate (3.8 ± 0.9 vs 2.6 ± 1.0,
P = 0.02) as shown in Table 1. However, the correla-
tion between quantitative levels of CD45 and GE
(Fig. 3B) or GCSI did not reach statistical significance
(Fig. 3E). The circular muscle CD45 expression was not
different in IG when compared to controls (16.5 ± 0.8
vs 14.3 ± 0.7 cells/high power field, P = 0.06).
Circular muscle nerve fiber loss There was a 14%
overall decrease in the PGP9.5 expression (38 ± 1.5 vs
44.3 ± 2.3 fibers/high power field, P = 0.01). Five of the
20 IG had a ‡ 25% dropout. Age and sex were similar
between those with and without PGP9.5 loss. Fur-
thermore, no correlations existed between PGP9.5
quantification and GE (Fig. 3C) and GCSI (Fig. 3F).
A B C
D E F
Figure 2 Correlations between ICC, CD45 positive myenteric plexus cells and PGP9.5 positive nerve fibers in diabetic gastroparesis. (A) ICC-PGP9.5
positive nerve fibers (r = 0.47, P = 0.03*, slope=0.11, 95% CI=0.008–0.2), (B) ICC-CD45 positive myenteric cells (r = 0.1, P = 0.65), (C) PGP9.5
positive nerve fibers-CD45 positive myenteric cells (r = 0.11, P = 0.63). Correlations between ICC, CD45 positive myenteric plexus cells and
PGP9.5 positive nerve fibers in idiopathic gastroparesis. (D) ICC-PGP9.5 positive nerve fibers (r = 0.32, P = 0.16), (E) ICC-CD45 positive myenter-
ic cells (r = )0.09, P = 0.71), (F) PGP9.5 positive nerve fibers-CD45 positive myenteric cells (r = 0.06, P = 0.78).
Table 2 Correlations between inhibitory (nNOS, VIP), excitatory (substance P) enteric nervous system and extrinsic innervation (tyrosine
hydroxylase) and 4 h gastric retention and GCSI score
nNOS
positive neurons
nNOS
positive nerve fibers
VIP positive
nerve fibers
SP positive
nerve fibers
TH positive
labeling
Diabetic gastroparesis
% Gastric retention at 4 h,
correlation coefficient (r)
)0.32 (P = 0.18) )0.03 (P = 0.89) )0.13 (P = 0.58) )0.35 (P = 0.15) )0.12 (P = 0.61)
GCSI average score,
correlation coefficient (r)
0.17 (P = 0.48) 0.21 (P = 0.45) 0.22 (P = 0.37) 0.20 (P = 0.47) )0.14 (P = 0.56)
Idiopathic gastroparesis
% Gastric retention at 4 h,
correlation coefficient (r)
0.13 (P = 0.61) )0.14 (P = 0.56) 0.22 (P = 0.34) 0.006 (P = 0.97) 0.25 (P = 0.31)
GCSI average score, correlation
coefficient (r)
0.17 (P = 0.45) 0.40 (P = 0.06) )0.27 (P = 0.26) 0.35 (P = 0.13) )0.14 (P = 0.56)
GCSI, gastroparesis cardinal symptom index score; nNOS, neuronal nitric oxide synthase; SP, substance P; TH, tyrosine hydroxylase; VIP, vasoactive
intestinal peptide.
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Correlation between ICC loss, nerve loss and immune
infiltrate Unlike DG, ICC, and nerve fiber loss were
not correlated with each other (Fig. 2D). There was no
correlation between ICC loss, nerve loss, and immune
infiltrate in IG.
Inhibitory (nNOS, VIP) and excitatory (SP) enteric
nervous system and extrinsic innervation (TH)
Table 2 shows correlation coefficients between nNOS
positive myenteric neurons, nNOS positive nerve
fibers, VIP, SP, TH with GE, and average GCSI. There
were no significant correlations between these markers
and GE or average GCSI.
DISCUSSION
Gastroparesis continues to be a clinically challenging
syndrome with limited insights into its pathophysiol-
ogy and no major breakthroughs in treatment
options.17 The cellular defects in human gastroparesis
had not been comprehensively studied until recently
and no substantive data is available on correlations
between various cellular defects and gastric function or
clinical symptoms. Interstitial cells of Cajal is a key
component of the gut control mechanisms.18 Loss of
ICC is the most common and most consistently
reported cellular defect in animal models of DG and
in human gastroparesis. Significant loss of ICC at
12 weeks was observed in gastric antrum of streptozo-
tocin induced diabetic rats,19 and similar observations
have been made in the non obese diabetic (NOD)
mice.20,21 Amongst human studies, profound loss of
ICC in the antrum in a third of patients with refractory
gastroparesis was seen.13 In another study, intramus-
cular ICC were lost in eight patients with severe
diabetes, along with loss of nNOS-neurons.22 ICC loss
correlated with development of delayed GE in NOD
mice.20 In human DG, ICC loss is associated with
disruption in the generation and propagation of elec-
trical slow waves, resulting in gastric dysrhyth-
mias12,13 associated with abnormal GE.23,24 Our
study, within the limitations of the relatively small
sample size, is the first to describe a positive correla-
tion between ICC loss and severity of the delay in GE
in human DG. The group with ICC loss had more than
twice gastric retention compared to those with normal
ICC.
Coordinated gastric motor function relies on intact
intrinsic and extrinsic sensorimotor innervation. It
requires acetylcholine and purinergic mediated excit-
atory stimuli25 but also VIP, carbon monoxide and
nitric oxide (NO) mediated inhibitory stimuli.26
Abnormalities in both of these ENS components have
been described in animal models of DG and humans.
Most common being loss of expression of nNOS.7 Both
nNOS knockout27 and pharmacological inhibition28
A B C
D E F
Figure 3 Correlations between % gastric retention at 4 h and average GCSI with ICC, CD45 positive myenteric plexus cells and PGP9.5 positive
nerve fibers in idiopathic gastroparesis (A) ICC and % gastric retention at 4 h (r = 0.21, P = 0.38), (B) CD45 positive cells and % gastric retention at 4 h
(r = )0.10, P = 0.68), (C) PGP9.5 nerve fibers and % gastric retention at 4 h (r = 0.22, P = 0.37), (D) ICC and GCSI-average (r = )0.34, P = 0.15), (E)
CD45 positive cells and GCSI-average (r = 0.36, P = 0.13), (F) PGP9.5 nerve fibers and GCSI-average (r = 0.20, P = 0.40).
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have been associated with delayed GE in animal
models. Human data on abnormalities in nNOS and
other components of ENS is sparse and is mostly in
form of case reports of diabetics with or without
gastroparesis8,10 with nearly no data on whether these
changes associate with gastric function and clinical
symptoms. Even less is known about ENS changes in
IG11,29. The current study provides the first compre-
hensive description of associations between ENS
defects and gastric function and symptoms in both
DG and IG. The decrease in pan-neuronal marker
PGP9.514 did not correlate with either GE or gastropa-
resis severity. This was perhaps not surprising consid-
ering relatively minor nerve dropout in DG (17%) and
IG (14%) when compared with controls. A study
comparing appendicial tissue of six diabetic patients
with controls found no differences in PGP9.5 expres-
sion.30 Overall nerve loss as measured by PGP9.5
immunoreactivity may be less common in gastropare-
sis than previously thought and it does not correlate
with GE or clinical symptoms. However, even minor
neuronal losses when combined with other abnormal-
ities may result in physiological changes. Also it is
possible that while the sample size in the current study
is the largest reported sample size may not have been
sufficient to achieve adequate power to detect differ-
ences for nerves and other markers. In accordance with
previous animal literature7,9,31,32 and case
reports,8,10,30 myenteric and muscle nNOS expression
trended to decrease in our DG and IG compared to
controls, but this did not reach significance. In addi-
tion, these changes did not correlate with GE or
clinical severity. It remains to be determined if mea-
surement of other forms of nNOS such as dimerized
nNOS correlates better with clinical features.33 Like-
wise, substance P immunostain trended towards a
decrease in gastroparetics compared to controls
(P = 0.06) but was also not associated with clinical
features or GE. Quantitative immunostaining for VIP
or extrinsic innervation (TH) were not different in
gastroparetics as compared to controls and were not
associated with GE or symptom severity.
Recent work has highlighted a potential role for
immune cells in the pathophysiology of gastroparesis.
In an animal study, development of diabetes was
associated with activation of a population of heme
oxygenase-1 (HO1) positive M2 macrophages (alterna-
tively activated, antiinflammatory).34 Mice that devel-
oped delayed GE showed selective loss of these
macrophages and activation of HO1 negative M1
macrophages (proinflammatory). In addition to our
report on myenteric CD45 immune cell infiltrate in
both DG and IG,14 Parkman et al. have also shown
presence of immune infiltrate in a separate cohort of
DG35 and Zarate et al. reported lymphocytic immune
infiltrate in muscle layer of a single patient with IG.11
In this study, we find that IG with an infiltrate scored
higher on average GCSI, especially the nausea subscale
suggesting that these cells might be important in
clinical symptomatology of patients with IG. On visual
grading, gastroparetics differed from controls on stain-
ing for macrophages (CD68) and not T (CD3, CD4,
CD8) or B lymphocytes (CD79) suggesting that this
infiltrate is from macrophages. A limitation is that
CD68, the most commonly used marker for human
macrophages36–38 is not entirely specific. Future stud-
ies are required to explore subpopulations of human
macrophages and secreted cytokines to determine if
selective loss or gain of a subtype of these macrophages
is more commonly associated with gastroparesis.
This study highlights the difficulties in correlating
symptoms with physiological or pathophysiological
end points. The association between symptoms and GE
has been an area of debate with several studies39
finding no correlation while others correlating fullness,
upper abdominal pain and reduced hunger with delayed
GE.40,41 More recently data from the GpCRC suggests
an association, albeit not very strong, between the
severity of GE and symptoms.4 Given the central
influence on symptom perception, the complex phys-
iological basis for GE and the presence of other factors
such as visceral hypersensitivity,42 this is not too
surprising. Future studies will need to compare gastric
segmental function and severity of the GE defect as
well as take into account central input on symptom
generation to decipher the relative contribution of each
factor to symptoms. Also, the region of the human
stomach that is most appropriate to biopsy and the
optimal size of the biopsy to account for patchiness21
remains to be determined. This study also highlights
potential differences in the pathophysiology of DG and
IG such as correlation between GE and ICC numbers
in DG but not IG and the stronger association between
immune cells and symptoms in IG.
In conclusion, this study describes correlations
between clinical, physiological and cellular changes
in a relatively large sample of prospectively enrolled
gastroparetics. The main findings of the paper are that
loss of ICC is associated with development of delayed
gastric emptying in DG and that non-lymphocytic
myenteric infiltrate correlates with overall clinical
severity and nausea in IG. Full thickness
gastric biopsies may help define specific cellular
abnormalities in gastroparesis some of which are
associated with physiological and clinical characteris-
tics of gastroparesis.
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APPENDIX
*Members of the Gastroparesis Clinical Research
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Stanford University, Stanford, CA, USA
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Nguyen, MD; Nighat Ullah, MD
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CA, USA
William Snape, MD (Principal Investigator); Robin
Bishop (2008); Nata DeVole, RN; Mary Greene, MS;
Sue Louiseau; Shelly Parker, RN MSN ANP-C ANP;
Eve Pillor, RN MSN FNP; Courtney Ponsetto, RN;
Katerina Shetler, MD
Mayo Clinic College of Medicine, Rochester,
MN, USA
Gianrico Farrugia, MD (Principal Investigator);
Madhusudan Grover, MD; Cheryl Bernard; Matt
Lurken (2007–2009); K. Robert Shen, MD; Michael
Sarr, MD; Michael Kendrick, MD
Temple University, Philadelphia, PA, USA
Henry P. Parkman, MD (Principal Investigator);Steven
Kantor; Vanessa Lytes, CRNP; Amiya Palit, MD;
Priyanka Sachdeva, MD; Kellie Simmons, RN; Sean
Harbison, MD
Texas Tech University Health Sciences Center,
TX, USA
Richard W. McCallum, MD (Principal Investigator);
Reza Hejazi, MD; Irene Sarosiek, MD; Denise Vasquez;
Natalia Vega
University of Michigan, Ann Arbor, MI, USA
William Hasler, MD (Principal Investigator); Michelle
Atkinson
University of Mississippi Medical Center,
Jackson, MS, USA
Thomas Abell, MD (Principal Investigator); JoAnne
Fordham; Olivia Henry, RD; Archana Kedar, MD;
Valerie McNair, LPN II; Danielle Spree, CNP
Wake Forest University, Winston-Salem, NC,
USA
Kenneth Koch, MD (Principal Investigator); Lynn
Baxter; Jorge Calles, MD; Samantha Culler; Judy
Hooker, RN; Paula Stuart, PA
Resource Centers
National Institute of Diabetes, Digestive and
Kidney Diseases, Bethesda, MD, USA
Frank Hamilton, MD, MPH (Project Scientist); Steven
James, MD; Rebecca Torrance, RN, MSN; Rebekah
Van Raaphorst, MPH
Johns Hopkins University, Bloomberg School of
Public Health (Data Coordinating Center),
Baltimore, MD, USA
James Tonascia, PhD (Principal Investigator); Patricia
Belt; Michele Donithan, MHS; Mika Green, MA;
Milana Isaacson; Linda Lee, MD; Kevin Patrick May;
Laura Miriel;Aynur U¨nalp-Arida, MD, PhD; Mark Van
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